SHANGHAI – It is no secret that China is heavy on generics and light on innovation. But what happens when a successful drugmaker with deep pockets and a visionary chairman decides to take on drug discovery? Haiyan Pharmaceutical Technology Co. Ltd., the drug development subsidiary of the Yangtze River Pharmaceutical Group (YRP), and its team of executive returnees are set to prove that innovation can be implanted anywhere, even in a risk adverse generics maker.